1 Dividend King to Buy and Hold Through Any Market

Core Insights - Johnson & Johnson (JNJ) is recognized as a Dividend King, having consistently paid and increased dividends for over 50 years, making it a stable investment option during market volatility [1] - JNJ stock outperformed the market with a 43.7% increase last year, compared to the market's overall gain of 16.6%, and has continued to rise by over 10% in early 2026 [2] Business Structure and Performance - In 2023, JNJ spun off its consumer division into a separate company called Kenvue (KVUE), allowing JNJ to focus on a pure-play health care innovation business centered on drugs and medical devices [4] - The Innovative Medicine segment is the primary revenue driver, generating $15.7 billion in Q4 2023, a 10% year-over-year increase, and $60.4 billion for the full year, reflecting a 6% increase [4] - JNJ reported a 5.3% increase in worldwide sales to $94.2 billion, despite challenges from the loss of exclusivity on Stelara, with adjusted diluted earnings per share rising 8.1% to $10.79 [4] Growth Prospects - Oncology is projected to achieve 21% operational sales growth in 2025, with anticipated annual sales exceeding $50 billion by 2030, marking it as a significant growth engine for the company [5] - The MedTech segment also showed strong performance, with a 7.5% revenue growth in Q4 and 6.1% for the full year, generating $34 billion in sales, driven by advancements in Cardiovascular, Surgery, and Vision [5] - JNJ's MedTech division is supported by over 60 active clinical trials and multiple regulatory submissions planned, positioning it as a key growth pillar alongside Pharmaceuticals [5][6]